CTRI/2021/08/035625尚未招募1 期
A comparartive study of the efficacy of once daily 4 % hydroquinone and 2% kojic acid cream for the treatment of facial melasma: A Randomized control trail
ROHAILKHAND MEDICAL COLLEGE0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Those who are willing for study
- •2. Moderate to severe melasma
- •3. Age (18-60) years.
- •4. Mentally stable, oriented and coherent patients.
排除标准
- •1. Pregnancy and Lactation
- •2. Melasma inducing drugs.
- •3. Patients on photosensitizing drugs or thyroid hormones.
- •4. Patients on Hormone replacement therapy
研究者
相似试验
尚未招募
不适用
Comparison of the efficacy of platelet rich plasma injection which extracted by two methods and placebo on pain, range of motion and function of patients with osteoarthritis of the kneeKnee Osteoarthritis.Osteoarthritis of kneeIRCT20140907019073N5Iran University of Medical Sciences45
进行中（未招募）
不适用
Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD)EUCTR2011-006050-91-SEovartis Pharma Service AG184
已完成
3 期
A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary disease (CQVA149A2326)COPDchronic obstructive pulmonary disease10038716NL-OMON37459ovartis Pharma BV70
进行中（未招募）
不适用
Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-006050-91-NLovartis Pharma Service AG184
进行中（未招募）
1 期
Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-006050-91-DKovartis Pharma Service AG184